DGAP-News: SYGNIS AG: First SYGNIS QualiPhi(R)-based products launched by QIAGEN

| Source: EQS Group AG
DGAP-News: SYGNIS AG / Key word(s): Product Launch
SYGNIS AG: First SYGNIS QualiPhi(R)-based products launched by QIAGEN

12.02.2014 / 09:00


Press Release

First SYGNIS QualiPhi(R)-based products launched by QIAGEN

  - Important milestone reached: SYGNIS places first product in the market 

  - QualiPhi(R), now renamed SensiPhi(R), targets sophisticated
    applications for DNA amplification.

Madrid, Spain and Heidelberg, Germany, February 12th, 2014 -SYGNIS AG
(Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that
its partner QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) the global
leader in sample and assay technologies, launched the first two products of
a series of kits based on SYGNIS' proprietary amplification technology
QualiPhi(R) now renamed SensiPhi(R). The two kits, REPLI-g WTA Single Cell
Kit and REPLI-g Cell WGA & WTA Kit, are available now and will be
commercialized globally through QIAGEN's established distribution channels.
The product launches result from a global exclusive license agreement with
QIAGEN signed in 2012.

'We are at the beginning of a series of product launches that we believe
will establish our polymerase as the potential future gold standard for
isothermal amplification of DNA', Pilar de la Huerta, CEO of SYGNIS stated.
'With the launch of the first products based on our proprietary technology,
SYGNIS continues to deliver on its objectives. It is a mark of our success
as a company to have our product commercialized by the world leader

 'We are very pleased with the launch of our new kits based on the
polymerase provided by SYGNIS', commented Achim Ribbe, Vice President
Corporate Business Development Licensing at QIAGEN. 'The REPLI-g WTA Single
Cell and REPLI-g Cell WGA & WTA address key user challenges in NGS and
other downstream applications, where DNA sequence analysis is limited by
small amounts down to single cells of available sample material. To drive
adoption of NGS in the clinical space, QIAGEN is building a broad portfolio
of universal products including the REPLI-g Single Cell Kits which are
compatible with any major NGS platform and which also support our own
integrated sample-to-insight GeneReader workflow currently in development.'

SensiPhi(R) is the second generation of a DNA polymerase that was licensed
from the Spanish National Research Council (CSIC) in 2010. Due to its
unique properties, first studies suggest that it has the potential to
improve the amplifications of whole genomes and large stretches of DNA.
SYGNIS' SensiPhi(R) is a high efficiency, high fidelity polymerase for DNA
amplification which conveys the outstanding properties in terms of speed,
accuracy and length of DNA fragments to be amplified. It differs from PCR
since it provides generic amplification of the complete genome, whereas PCR
is designed to detect predefined target sequences, and therefore only
amplifies specific, mostly very short fragments of the DNA.

For further information please contact:


Pilar de la Huerta
Tel: +34-918063089
Email: pdelahuerta@sygnis.es


About SYGNIS AG: www.sygnis.com
After the merger in 2012 between X-Pol Biotech, specializing in DNA
amplification and sequencing, and SYGNIS AG, listed in the German Stock
Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS'
new mission is to develop and distribute technologies and products from
X-Pol, which has a commercial product in the DNA amplification segment,
SensiPhi(R) and is currently developing other products in the field of Next
Generation Sequencing.

### Disclaimer
This publication is intended for information only and constitutes neither
an offer to sell nor an invitation to buy securities. Some statements
included in this press release, relating neither to proven financial
results nor other historical data, should be viewed as forward-looking,
i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered
to be total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and goals of
SYGNIS AG may deviate greatly from the established conclusions or implied
predictions contained in such statements. SYGNIS does not undertake to
publicly update or revise these statements in the light of new information
or future results or for any other reason.###

End of Corporate News


12.02.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language:    English                                               
Company:     SYGNIS AG                                             
             Im Neuenheimer Feld 515                               
             69120 Heidelberg                                      
Phone:       06221 454-6                                           
Fax:         06221 454-700                                         
E-mail:      contact@sygnis.de                                     
Internet:    www.sygnis.de                                         
ISIN:        DE000A1RFM03                                          
WKN:         A1RFM0                                                
Listed:      Regulierter Markt in Frankfurt (Prime Standard);      
             Freiverkehr in Berlin, Düsseldorf, Hamburg, München,  
End of News    DGAP News-Service  
252200 12.02.2014